User Controlled Follow-up of Epilepsy

Overview

In December 2019 Vestre Viken Hospital Trust implemented user controlled epilepsy follow-up. Patients receive follow-up questions digitally twice yearly. The questionnaire was made by a multidisciplinary national network of epilepsy experts (EpilepsiNett). Responses to the questionnaire are controlled by an epilepsy nurse, and further follow-up is based on this. Data collected for user controlled follow-up will be matched with data from national registries, investigating whether this type of follow-up influences the patients' clinical course and/or the hospital's and society's use of resources.

Full Title of Study: “Effects of EpilepsiNett – User Controlled Follow-up Developed by a Nationwide, Multidisciplinary Network of Epilepsy Experts”

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 31, 2023

Detailed Description

Vestre Viken Hospital Trust implemented user controlled follow-up by means of PROMs reported digitally in December 2019. Whenever they want to, but minimum every six months, users respond to standardized follow-up questions developed by the experts of EpilepsiNett, a multidisciplinary national network of epilepsy researchers. This ensures that a broader range of topics are covered, not just those related to seizures and adverse events. The incoming responses are handled by a trained epilepsy nurse, who contact the patient when needed, consulting the responsible medical doctor when needed. If current issues cannot be solved by telephonic contact with the epilepsy nurse and/or responsible medical doctor, the patient is offered an appointment at the outpatient clinic. In collaboration with the Norwegian Institute of Public Health (FHI), the aim is to make user controlled epilepsy follow-up by means of PROMs a national standard for epilepsy care in Norway. In order to achieve this, data and documentation of its effects is crucial. From Vestre Viken's internal reporting system, the investigators will extract the number of consultations in the outpatient clinic of neurology with a diagnostic code of epilepsy (ICD-10 G40.0-G40.9) for the years 2017-2019 and calculate a yearly average (total and per patient) of epilepsy-related visits before implementation of user-controlled epilepsy follow-up (Dec. 2019). The investigators will then extract the same data for the years 2020, 2021 and 2022 and compare to the mentioned average. Prevalence and incidence of epilepsy are expected to be stable across these years, but visits in the outpatient clinic are expected to be lower in the pandemic years of 2020 and 2021. Thus, the results from 2022 will be important. The same calculations will be done for visits to the emergency room outpatient clinic, and for emergency hospital admissions. Data will be extracted from the digitally registered PROMs at Drammen Hospital (Dec. 2019-Dec. 2022) and Haukeland University Hospital (Dec. 2020-Dec. 2022). The investigators will analyze adherence, seizure frequency and quality of life in all patients included in user controlled epilepsy follow-up at baseline, and after two years of such follow-up. Data from national registries will also be used. EpilepsiNett has received a large registry based data package, combining variables several Norwegian health registries. The connection of data from the different registries will be done by The Norwegian Prescription Database, including a file with IDs of the patients included in user controlled epilepsy follow-up, and delivers a pseudonymized file to the head of research of EpilepsiNett, who controls and distributes the data to our researchers.

Interventions

  • Other: User controlled epilepsy follow-up by means of patient reported outcome measures (PROM)
    • Whenever they want to, but minimum every six months, users respond to standardized follow-up questions developed by the experts of EpilepsiNett. This ensures that a broader range of topics are covered, not just those related to seizures and adverse events. The incoming responses are handled by a trained epilepsy nurse, who contact the patient when needed, consulting the responsible medical doctor when needed. If current issues cannot be solved by telephonic contact with the epilepsy nurse and/or responsible medical doctor, the patient is offered an appointment at the outpatient clinic.

Arms, Groups and Cohorts

  • Adults with epilepsy
    • User controlled epilepsy follow-up by means of digital patient reported outcome measures (PROM).

Clinical Trial Outcome Measures

Primary Measures

  • Number of visits to the outpatient clinic before and after implementation of user controlled epilepsy follow-up
    • Time Frame: 2 years
    • We hypothesize a decline in outpatient clinic visits for the people enrolled in user controlled epilepsy follow-up
  • Number of emergency hospitalizations before and after implementation of user controlled epilepsy follow-up
    • Time Frame: 2 years
    • We hypothesize a decline in emergency hospitalization for the people enrolled in user controlled epilepsy follow-up

Participating in This Clinical Trial

Inclusion Criteria

Diagnosis of epilepsy. Age>18 years. Exclusion Criteria:

Not able to handle the digital tools required for this type of follow-up.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Vestre Viken Hospital Trust
  • Collaborator
    • Haukeland University Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Marte Syvertsen, PhD, Study Chair, Vestre Viken Hospital Trust
  • Overall Contact(s)
    • Marte Syvertsen, PhD, +4732803575, marsyv@vestreviken.no

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.